Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Gains from Investment Securities (2016 - 2025)

ImmunityBio (IBRX) has disclosed Gains from Investment Securities for 12 consecutive years, with $307000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 72.29% to $307000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $307000.0, a 72.29% decrease, with the full-year FY2025 number at $307000.0, down 72.29% from a year prior.
  • Gains from Investment Securities was $307000.0 for Q4 2025 at ImmunityBio, up from -$307000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.8 million in Q3 2021 to a low of -$4.8 million in Q4 2021.
  • A 5-year average of -$38333.3 and a median of $8000.0 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: crashed 707.78% in 2021, then skyrocketed 13750.0% in 2024.
  • ImmunityBio's Gains from Investment Securities stood at -$4.8 million in 2021, then soared by 58.69% to -$2.0 million in 2022, then soared by 100.4% to $8000.0 in 2023, then surged by 13750.0% to $1.1 million in 2024, then crashed by 72.29% to $307000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Gains from Investment Securities are $307000.0 (Q4 2025), -$307000.0 (Q3 2025), and $307000.0 (Q2 2025).